Next steps should include a clinical trial for the drug in patients considered at high risk of colorectal cancer, such as those with a strong family history, multiple previous polyps and chronic intestinal inflammation like colitis, said corresponding author of the study Darren Browning from the Medical College of Georgia at the Augusta University.